BRPI0408802B8 - método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão - Google Patents

método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão

Info

Publication number
BRPI0408802B8
BRPI0408802B8 BRPI0408802A BRPI0408802A BRPI0408802B8 BR PI0408802 B8 BRPI0408802 B8 BR PI0408802B8 BR PI0408802 A BRPI0408802 A BR PI0408802A BR PI0408802 A BRPI0408802 A BR PI0408802A BR PI0408802 B8 BRPI0408802 B8 BR PI0408802B8
Authority
BR
Brazil
Prior art keywords
ngal
renal
lesion
detecting
cell injury
Prior art date
Application number
BRPI0408802A
Other languages
English (en)
Inventor
M Barasch Jonathan
Devarajan Prased
Original Assignee
Childrens Hospital Med Ct
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408802(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hospital Med Ct, Univ Columbia filed Critical Childrens Hospital Med Ct
Publication of BRPI0408802A publication Critical patent/BRPI0408802A/pt
Publication of BRPI0408802B1 publication Critical patent/BRPI0408802B1/pt
Publication of BRPI0408802B8 publication Critical patent/BRPI0408802B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

"método e kit para detectar o início precoce de lesão de células tubulares renais". a presente invenção refere-se a um método e kit para detectar o início precoce de lesão de células tubulares renais, utilizando ngal como um biomarcador urinário precoe. ngal é um pequeno polipeptídeo secretado que é resistente à protease e conseqüentemente prontamente detectado na urina após lesão de células dos túbulos renais. a expressão da proteína ngal é detectada predominantemente em células dos túbulos proximais, em uma distribuição citoplasmáica pontilhada reminiscente de uma proteína secretada. o aparecimento de ngal na urina está relacionado com a dose e a duração de isquemia renal e nefrotoxemia, e é diagnóstico de lesão de células dos túbulos renais e falência renal. a detecção por ngal também é um marcador útil para monitorar os efeitos colaterais nefrotóxicos de fármacos ou outros agentes terapêuticos.
BRPI0408802A 2003-03-27 2004-03-26 método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão BRPI0408802B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45814303P 2003-03-27 2003-03-27
US60/458,143 2003-03-27
US48159603P 2003-11-04 2003-11-04
US60/481,596 2003-11-04
PCT/US2004/009191 WO2004088276A2 (en) 2003-03-27 2004-03-26 A method and kit for detecting the early onset of renal tubular cell injury

Publications (3)

Publication Number Publication Date
BRPI0408802A BRPI0408802A (pt) 2006-04-04
BRPI0408802B1 BRPI0408802B1 (pt) 2019-08-20
BRPI0408802B8 true BRPI0408802B8 (pt) 2021-07-27

Family

ID=33135089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408802A BRPI0408802B8 (pt) 2003-03-27 2004-03-26 método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão

Country Status (14)

Country Link
US (11) US20040219603A1 (pt)
EP (3) EP2360475B1 (pt)
JP (2) JP5392980B2 (pt)
CN (1) CN102183656B (pt)
AT (1) ATE437371T1 (pt)
AU (1) AU2004225472B2 (pt)
BR (1) BRPI0408802B8 (pt)
CA (1) CA2520658A1 (pt)
DE (1) DE602004022150D1 (pt)
DK (2) DK2360475T3 (pt)
ES (3) ES2330005T5 (pt)
MX (1) MXPA05010385A (pt)
NZ (1) NZ543028A (pt)
WO (1) WO2004088276A2 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003281A (es) 2000-10-13 2004-05-21 Childrens Medical Center Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2565701A1 (en) * 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
ES2703434T3 (es) * 2004-12-20 2019-03-08 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7858324B2 (en) * 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US20100062537A1 (en) * 2005-11-30 2010-03-11 Harald Mischak Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO)
WO2007125385A2 (en) * 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
CN101421622A (zh) 2006-02-17 2009-04-29 儿童医学中心公司 作为癌症生物标志物的游离ngal
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
JP2010500535A (ja) * 2006-08-07 2010-01-07 アンチボディショップ・アクティーゼルスカブ 重大な腎損傷を除外するための診断検査
GB0617429D0 (en) * 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
EP2095106B1 (en) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2500723B1 (en) * 2006-11-14 2015-07-08 Alere San Diego, Inc. Methods for monitoring and risk prediction in cardiorenal syndrome
CN101730529A (zh) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 用于治疗代谢疾病和糖尿病的方法、化合物和组合物
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
ES2532220T3 (es) * 2007-03-26 2015-03-25 Novartis Ag Biomarcadores de seguridad renal predictiva y señales de biomarcadores para monitorizar la función renal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
PL2215481T5 (pl) † 2007-11-15 2017-10-31 Bioporto Diagnostics As Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera
WO2009114699A2 (en) * 2008-03-12 2009-09-17 The Trustees Of Columbia University In The City Of New York High molecular weight ngal as a biomarker for chronic kidney disease
US20090239242A1 (en) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early identification and prediction of kidney injury
US20090238812A1 (en) 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
HUP0800448A2 (en) * 2008-07-21 2011-02-28 Pecsi Tudomanyegyetem Diagnosis of systemic diseases
US20120083421A1 (en) * 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
CA2742291A1 (en) * 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, andmethods of enrichment, analysis and use
US20110287964A1 (en) * 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
US9476880B2 (en) * 2008-11-21 2016-10-25 Future Medical Diagnostics Co., Ltd. Methods, devices and kits for detecting or monitoring acute kidney injury
ES2530574T3 (es) * 2009-01-28 2015-03-03 Ind Tech Res Inst Biomarcadores asociados a la nefropatía
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
WO2011000938A1 (de) * 2009-07-02 2011-01-06 Mosaiques Diagnostics And Therapeutics Ag Verfahren und marker zur diagnose eines akuten nierenversagens
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN103080743B (zh) * 2010-06-23 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012068545A1 (en) * 2010-11-18 2012-05-24 Jonathan Barasch Ngal in acute kidney injury
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
US9387031B2 (en) * 2011-07-29 2016-07-12 Medtronic Ablation Frontiers Llc Mesh-overlayed ablation and mapping device
KR20140074307A (ko) * 2011-08-26 2014-06-17 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY
EP3736570A1 (en) 2019-05-09 2020-11-11 Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León Method for the diagnosis, sub-classification and prognosis of acute kidney injury by detecting cct7
CN112076309A (zh) * 2020-07-27 2020-12-15 南通大学 一种环状促红素衍生肽在肾损伤和环孢素a损伤保护中的应用
WO2022082013A1 (en) * 2020-10-16 2022-04-21 Lmx Medtech Llc Method for correction for urine volume
CN113083264A (zh) * 2021-04-16 2021-07-09 郑州大学 二氧化硅-金属有机骨架核壳型复合材料及其在硫醇小分子检测方面的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4731326A (en) * 1984-06-04 1988-03-15 Ortho Diagnostic Systems Inc. Disease diagnosis by detection of shed normal tissue antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
IL85257A (en) * 1987-02-10 1993-02-21 Tanabe Seiyaku Co Pharmaceutical compositions containing 2-(4-methoxyphenyl) 3-acetoxy-5-- (2-(dimethylamino) ethyl) -8-chloro-2,3- dihydro-1,5-benzothiazepin -4 (5h)-one having renal function-improving effect and diuretic effect
US4900662A (en) * 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
EP0575906A2 (en) * 1992-06-19 1993-12-29 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Sandwich immunoassay of beta-N-acetylglucosaminidase and monoclonal antibody used therein
SE9401351D0 (sv) * 1994-04-21 1994-04-21 Venge A method for diagnosis
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
CA2233845A1 (en) * 1995-10-02 1997-04-10 Judah Weinberger Biochemical markers of ischemia
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
DE69735364T3 (de) * 1996-05-24 2010-05-06 Biogen Idec Ma Inc., Cambridge Modulatoren für die regenerierung von gewebe
US5945294A (en) * 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
JP3334558B2 (ja) * 1997-04-23 2002-10-15 富士レビオ株式会社 酵素免疫測定方法及び試験片
US6461827B1 (en) * 1997-04-30 2002-10-08 Mauha Corporation Methods and kits for detecting or predicting ischemic disorders
WO1999007740A2 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
AU5330200A (en) * 1999-06-18 2001-01-09 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
US20020160495A1 (en) * 2000-09-20 2002-10-31 University Of Medicine And Dentistry Soluble ischemia activated protein
AU9396401A (en) * 2000-10-03 2002-04-15 Rowett Res Inst Method of assaying pyrrole-containing biological compounds
MXPA03003281A (es) * 2000-10-13 2004-05-21 Childrens Medical Center Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2002089657A2 (en) * 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
EP1390497A2 (en) * 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
WO2004006941A1 (en) * 2002-07-17 2004-01-22 Index Pharmaceuticals Ab Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
CN1220487C (zh) * 2003-03-26 2005-09-28 浙江大学 复方肾保护氨基酸组合物及其应用
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ES2703434T3 (es) * 2004-12-20 2019-03-08 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions

Also Published As

Publication number Publication date
ES2754753T3 (es) 2020-04-20
JP2011221033A (ja) 2011-11-04
MXPA05010385A (es) 2006-03-08
ATE437371T1 (de) 2009-08-15
EP1616184B1 (en) 2009-07-22
NZ543028A (en) 2008-06-30
ES2330005T5 (es) 2018-06-20
US20130183693A1 (en) 2013-07-18
US20100227418A1 (en) 2010-09-09
JP2006521565A (ja) 2006-09-21
ES2330005T3 (es) 2009-12-03
US20120028371A1 (en) 2012-02-02
US20150185231A1 (en) 2015-07-02
CN102183656A (zh) 2011-09-14
EP2360475B1 (en) 2019-10-02
WO2004088276A3 (en) 2004-11-25
EP2083270A1 (en) 2009-07-29
JP5392980B2 (ja) 2014-01-22
US20130137116A1 (en) 2013-05-30
US20090181407A1 (en) 2009-07-16
EP2360475A1 (en) 2011-08-24
US20040219603A1 (en) 2004-11-04
EP1616184A2 (en) 2006-01-18
AU2004225472B2 (en) 2011-02-10
CN102183656B (zh) 2014-04-16
WO2004088276A2 (en) 2004-10-14
AU2004225472A1 (en) 2004-10-14
EP1616184B2 (en) 2018-05-30
DK1616184T3 (da) 2009-10-19
CA2520658A1 (en) 2004-10-14
US20100233728A1 (en) 2010-09-16
EP1616184A4 (en) 2006-07-12
BRPI0408802A (pt) 2006-04-04
DK1616184T4 (en) 2018-08-13
DK2360475T3 (da) 2020-01-06
ES2739463T3 (es) 2020-01-31
US20070254370A1 (en) 2007-11-01
DE602004022150D1 (de) 2009-09-03
US20090123941A1 (en) 2009-05-14
US20130137191A1 (en) 2013-05-30
EP2083270B1 (en) 2019-06-12
BRPI0408802B1 (pt) 2019-08-20

Similar Documents

Publication Publication Date Title
BRPI0408802B8 (pt) método para a detecção de uma lesão de célula tubular renal isquêmica e método para identificar a extensão desta lesão
EP1766395A4 (en) PROCESS FOR EARLY DETECTION OF A CHILDNESS AND INJURY
Clark et al. Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects
WO2006073682A3 (en) Diagnostic test
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
DE60129314D1 (de) Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
FR2816411B1 (fr) Moyens de detection de la transformation pathologique de la proteine app et leurs applications
Gerling et al. Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis
ATE191976T1 (de) Verfahren zum nachweis von knochen- und anderen bindegewebeerkrankungen in menschen und tieren
Manon‐Jensen et al. Altered collagen turnover in factor VIII‐deficient rats with hemophilic arthropathy identifies potential novel serological biomarkers in hemophilia
ATE433991T1 (de) Morbus-crohn-antikörperepitoppeptid und reagens zum testen auf morbus crohn
AU4121900A (en) Methods and test kits for evaluating the presence and severity of respiratory tract inflammation
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
BR0308095A (pt) Teste para anticorpos anti-ingap
BR0111975A (pt) Fator, composição, veìculo, ligando, kits de diagnósticos, processos para detectar uma prpsc em uma amostra, e para remover prpsc de material biológico, método para diagnosticar encefalopatias espongiformes humanas transmissìveis e encefalopatias de prìons de animais, e, uso de um fator
JP2004516038A5 (pt)
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
ES2706539T3 (es) Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
Porcher et al. Biological markers as indicators of exposure and pneumoconiotic risk: prospective study
DE60115453D1 (de) Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
WO2006046250A3 (en) Compositions and methods for diagnosing and treating insulin resistance
Brittain et al. 109 CHARACTERIZATION OF METALLOPROTEINASE CLEAVAGE PRODUCTS OF HUMAN ARTICULAR CARTILAGE
Rabey et al. ESll0 Clinimetry of cognition and behavior in Parldnson's disease
Illarramendi Rojas et al. Cutaneous lesions sensory impairment recovery and nerve regeneration in leprosy patients

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO